Section R12-1-723. Training for Use of Unsealed Radioactive Mate- rial Requiring a Written Directive, Including Treatment of Hyperthyroidism, and Treatment of Thyroid Carcinoma

A.      Except as provided in R12-1-710, the licensee shall require an authorized user of unsealed radioactive material for the uses authorized under Group 300 to be a physician who:

1.	Is certified by a medical specialty board whose certifica-		least        three        cases        in       Category
	tion  process   has  been  recognized  by  the  NRC  or  an		(A)(2)(b)(vi)(2) also satisfies this require-
	Agreement State and who meets the requirements in sub-		ment);
	section (A)(2). To have its certification process recog-		(2)   Oral administration of greater than 1.22
	nized, a specialty board shall require all candidates for		gigabecquerels (33 millicuries) of sodium
	certification to:		iodide I-131;
	a.      Successfully complete residency training in a radia-		(3)   Parenteral administration of any beta emit-
	tion therapy or nuclear medicine training program or		ter, or a photon-emitting radionuclide with
	a program in a related medical specialty. These resi-		a photon energy less than 150 keV, for
	dency training programs must include 700 hours of		which a written directive is required; and/
	training and experience as described in (A)(2). Eligi-		or
	ble training programs must be approved by the Resi-		(4)   Parenteral   administration  of  any  other
	dency  Review  Committee   of  the   Accreditation		radionuclide, for which a written directive
	Council for Graduate Medical Education, the Royal		is required; and
	College of Physicians and Surgeons of Canada, or		c.      Has obtained written attestation, signed by a precep-
	the  Committee  on  Post-Graduate  Training  of  the		tor authorized user who meets the requirements as
	American Osteopathic Association; and		an authorized user for Exhibit A group 300 nuclides,
	b.     Pass an examination, administered by diplomates of		NRC, or equivalent Agreement State requirements,
	the specialty board, which tests knowledge and com-		that the individual has satisfactorily completed the
	petence in radiation safety, radionuclide handling,		requirements in subsection (A)(1) or (A)(2) and has
	and quality assurance, and clinical use of unsealed		achieved a level of competency sufficient to func-
	radioactive material for which a written directive is		tion  independently   as  an  authorized  user  for  the
	required; or		medical  uses  authorized  under  Exhibit  A  of  this
2.	Has completed  700 hours of training and  experience,		Article. The written attestation must be signed by a
	including a minimum of 200 hours of classroom and lab-		preceptor authorized user who meets the require-
	oratory  training,  in   basic  radionuclide  handling  tech-		ments in this Section, NRC, or equivalent Agree-
	niques   applicable   to    the   medical   use   of   unsealed		ment State requirements. The preceptor authorized
	radioactive material requiring a written directive. The		user, who meets the requirements in subsection (B)
	training and experience must include:		must have experience in administering dosages in
	a.      Classroom and laboratory training in the following		the same dosage category or categories as the indi-
	areas:		vidual requesting authorized user status.
	i.      Radiation physics and instrumentation;	B.	Except as provided in R12-1-710, a licensee shall require an
	ii.     Radiation protection;		authorized user of iodine-131 for the oral administration of
	iii.   Mathematics pertaining to the use and measure-		sodium iodide I-131 requiring a written directive in quantities
	ment of radioactivity;		less than or equal to 1.22 gigabecquerels (33 millicuries) to be
	iv.   Chemistry of radioactive material for medical		a physician who has completed the training requirements in 10
	use; and		CFR 35.392, January 1, 2013, incorporated by reference, and
	v.     Radiation biology; and		available under R12-1-101. This incorporated material con-
	b.     Work experience, under the supervision of an autho-		tains no future editions or amendments.
	rized user who meets the requirements in this Arti-	C.	Except as provided in R12-1-710, a licensee shall require an
	cle,      NRC,    or     equivalent        Agreement        State		authorized user of iodine-131 for the oral administration of
	requirements, involving:		sodium iodide I-131 requiring a written directive in quantities
	i.      Ordering, receiving, and unpacking radioactive		greater than 1.22 gigabecquerels (33 millicuries) to be a physi-
	materials  safely  and   performing  the   related		cian who has completed the training requirements in 10 CFR
	radiation surveys;		35.394, January 1, 2013, incorporated by reference, and avail-
	ii.     Performing   quality   control   procedures   on		able under R12-1-101. This incorporated material contains no
	instruments used to determine the activity of		future editions or amendments.
	dosages  and  performing   checks  for  proper	D.	Except as provided in R12-1-710, a licensee shall require an
	operation of survey meters;		authorized user for the parenteral administration of unsealed
	iii.   Calculating, measuring, and safely preparing		radioactive material requiring a written directive to be a physi-
	patient or human research subject dosages;		cian who has completed the training requirements in 10 CFR
	iv.   Using administrative controls to prevent a med-		35.396, January 1, 2013, incorporated by reference, and avail-
	ical event involving the use of unsealed radio-		able under R12-1-101. This incorporated material contains no
	active material;		future editions or amendments.
	v.     Using procedures to contain spilled radioactive	E.	The training and experience shall have been obtained within
	material safely and using proper decontamina-		the seven years preceding the date of application or the indi-
	tion procedures;		vidual shall have had related continuing education and experi-
	vi.   Administering dosages of radioactive drugs to		ence   since    the   required   training   and   experience   was
	patients or human research subjects involving a		completed.

minimum of three cases in each of the follow- ing categories for which the individual is requesting authorized user status:

(1)     Oral administration of less than or equal to

1.22 gigabecquerels (33 millicuries) of sodium iodide I-131, for which a written directive is required (Experience with at

Historical Note

New Section made by final rulemaking at 13 A.A.R. 1217, effective May 5, 2007 (Supp. 07-1). Amended by

final rulemaking at 20 A.A.R. 324, effective March 8,

2014 (Supp. 14-1).